Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops

References

• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye & Contact Lens. 2014;40(4):248–56. doi:10.1097/ICL.0000000000000042.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Irkec M, Messmer EM, Benitez-Del-Castillo JM, Bonini S, Figueiredo FC, Geerling G, Labetoulle M, Lemp M, Rolando M, et al. Clinical impact of inflammation in dry eye disease: proceedings of the Odyssey group meeting. Acta Ophthalmol. 2018;96(2):111–19. doi:10.1111/aos.13436.
   PubMed Web of Science ®Google Scholar
• Ambroziak AM, Szaflik J, Szaflik JP, Ambroziak M, Witkiewicz J, Skopinski P. Immunomodulation on the ocular surface: a review. Cent Eur J Immunol. 2016;41(2):195–208. doi:10.5114/ceji.2016.60995.
   PubMed Web of Science ®Google Scholar
• Calonge M, Enriquez-de-Salamanca A, Diebold Y, Gonzalez-Garcia MJ, Reinoso R, Herreras JM, Corell A. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm. 2010;18(4):244–53. doi:10.3109/09273941003721926.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, et al. TFOS dews ii definition and classification report. Ocul Surf. 2017;15(3):276–83. doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455–59. doi:10.1136/bjo.2007.132621.
   PubMed Web of Science ®Google Scholar
• Sy A, O’Brien KS, Liu MP, Cuddapah PA, Acharya NR, Lietman TM, Rose-Nussbaumer J. Expert opinion in the management of aqueous deficient dry eye disease (DED). BMC Ophthalmol. 2015;15:133. doi:10.1186/s12886-015-0122-z.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CSA phase 3 study group. Ophthalmology. 2000;107:631–39.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue J-S, Figueiredo FC, Baudouin C. Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–96. doi:10.5301/ejo.5000779.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue JS, Bonini S, Leonardi A. A randomized study of the efficacy and safety of 0.1% cyclosporine a cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520–30. doi:10.5301/EJO.5000952.
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–15. doi:10.1016/j.jtos.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Lifitegrast for the treatment of dry eye disease: results of a phase iii, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60. doi:10.1016/j.ophtha.2016.09.025.
   PubMed Web of Science ®Google Scholar
• Godin M, Gupta P. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin Ophthalmol. 2017;11:951–57. doi:10.2147/OPTH.S117188.
   PubMed Web of Science ®Google Scholar
• Hubner S, Dejager L, Libert C, Tuckermann JP. The glucocorticoid receptor in inflammatory processes: transrepression is not enough. Biol Chem. 2015;396(11):1223–31. doi:10.1515/hsz-2015-0106.
   PubMed Web of Science ®Google Scholar
• Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–47. doi:10.1038/nri.2017.1.
   PubMed Web of Science ®Google Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20(4):407–16. doi:10.1038/sj.eye.6701895.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55–72. doi:10.1007/s40123-013-0020-5.
   PubMedGoogle Scholar
• Jung HH, Ji YS, Sung MS, Kim KK, Yoon KC. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjogren’s syndrome. Chonnam Med J. 2015;51(1):26–32. doi:10.4068/cmj.2015.51.1.26.
   PubMedGoogle Scholar
• Daull P, Feraille L, Barabino S, Cimbolini N, Antonelli S, Mauro V, Garrigue JS. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res. 2016;153:159–64. doi:10.1016/j.exer.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Riancho L, Ismail D, Deniaud M, Amrane M, Baudouin C. Correlation between the inflammatory marker HLA-DR and signs and symptoms in moderate to severe dry eye disease HLA-DR quantification and DED characteristics. Invest Ophthalmol Vis Sci. 2017;58(4):2438–48. doi:10.1167/iovs.15-16555.
   PubMed Web of Science ®Google Scholar
• Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80–85.
   PubMed Web of Science ®Google Scholar
• Chast F, Lemare F, Legeais JM, Batista R, Bardin C, Renard G. [cyclosporine 2% eye drops preparation]. J Fr Ophtalmol. 2004;27:567–76.
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–38. doi:10.1016/j.survophthal.2009.02.002.
   PubMed Web of Science ®Google Scholar
• Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367–70.
   PubMed Web of Science ®Google Scholar
• Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109:S67–79.
   PubMed Web of Science ®Google Scholar
• Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31(3):271–85. doi:10.1016/j.preteyeres.2012.02.003.
   PubMed Web of Science ®Google Scholar
• Zhou L, Beuerman RW, Chan CM, Zhao SZ, Li XR, Yang H, Tong L, Liu S, Stern ME, Tan D. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res. 2009;8(11):4889–905. doi:10.1021/pr900686s.
   PubMed Web of Science ®Google Scholar
• Zhou L, Beuerman RW. Tear analysis in ocular surface diseases. Prog Retin Eye Res. 2012;31(6):527–50. doi:10.1016/j.preteyeres.2012.06.002.
   PubMed Web of Science ®Google Scholar
• Soria J, Acera A, Duran JA, Boto-de-Los-Bueis A, Del-Hierro-Zarzuelo A, Gonzalez N, Reigada R, Suarez T. The analysis of human conjunctival epithelium proteome in ocular surface diseases using impression cytology and 2D-DIGE. Exp Eye Res. 2018;167:31–43. doi:10.1016/j.exer.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Perumal N, Funke S, Pfeiffer N, Grus FH. Proteomics analysis of human tears from aqueous-deficient and evaporative dry eye patients. Sci Rep. 2016;6:29629. doi:10.1038/srep29629.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chauhan SK, Shao C, Omoto M, Inomata T, Dana R. IFN-gamma-expressing th17 cells are required for development of severe ocular surface autoimmunity. J Immunol. 2017;199(3):1163–69. doi:10.4049/jimmunol.1602144.
   PubMed Web of Science ®Google Scholar
• Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154(1):63–71. doi:10.1016/j.ajo.2012.01.034.
   PubMed Web of Science ®Google Scholar
• Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder SC. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632–38.
   PubMed Web of Science ®Google Scholar
• Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46(8):2766–71. doi:10.1167/iovs.04-1326.
   PubMed Web of Science ®Google Scholar
• French decree n° 2013-118, dated February 01, 2013 publishing the European directive 2010/63/ue. J. Offic. Rep. Fr. 2013; text 24 out of 130. 2013.
   Google Scholar
• Barabino S, Antonelli S, Cimbolini N, Mauro V, Bouzin M. The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye. Invest Ophthalmol Vis Sci. 2014;55(10):6499–504. doi:10.1167/iovs.14-14548.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J. 1995;21:221–32.
   PubMedGoogle Scholar
• Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. 2010;51(6):3083–91. doi:10.1167/iovs.09-3838.
   PubMed Web of Science ®Google Scholar
• Kodati S, Chauhan SK, Chen Y, Dohlman TH, Karimian P, Saban D, Dana R. Ccr7 is critical for the induction and maintenance of th17 immunity in dry eye disease. Invest Ophthalmol Vis Sci. 2014;55(9):5871–77. doi:10.1167/iovs.14-14481.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chauhan SK, Lee HS, Saban DR, Dana R. Chronic dry eye disease is principally mediated by effector memory th17 cells. Mucosal Immunol. 2014;7(1):38–45. doi:10.1038/mi.2013.20.
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD 3rd, Fang B, Zheng X, Ma P, Farley WJ, Siemasko KF, Niederkorn JY, et al. Il-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243–53. doi:10.1038/mi.2009.5.
   PubMed Web of Science ®Google Scholar
• Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H. Analysis of th17-associated cytokines and clinical correlations in patients with dry eye disease. PLoS One. 2017;12(4):e0173301. doi:10.1371/journal.pone.0173301.
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Dana R, Calonge M, Niederkorn JY, Pflugfelder SC. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 2010;3(5):425–42. doi:10.1038/mi.2010.26.
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Pangelinan SB, Chang E, Yoon KC, Farley WJ, Li DQ, Pflugfelder SC. Essential role for c-jun n-terminal kinase 2 in corneal epithelial response to desiccating stress. Arch Ophthalmol. 2009;127(12):1625–31. doi:10.1001/archophthalmol.2009.316.
   PubMedGoogle Scholar
• Chotikavanich S, de Paiva CS, Li de Q, Jj C, Bian F, Wj F, Pflugfelder SC. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203–09. doi:10.1167/iovs.08-2476.
   PubMed Web of Science ®Google Scholar
• Hyeon J, Cho SY, Hong ME, Kang SY, Do I, Im YH, Cho EY. Nanostring ncounter(r) approach in breast cancer: a comparative analysis with quantitative real-time polymerase chain reaction, in situ hybridization, and immunohistochemistry. J Breast Cancer. 2017;20(3):286–96. doi:10.4048/jbc.2017.20.3.286.
   PubMed Web of Science ®Google Scholar
• Thomassen MJ, Antal JM, Divis LT, Wiedemann HP. Regulation of human alveolar macrophage inflammatory cytokines by tyloxapol: a component of the synthetic surfactant exosurf. Clin Immunol Immunopathol. 1995;77:201–05.
   PubMedGoogle Scholar
• Ghio AJ, Marshall BC, Diaz JL, Hasegawa T, Samuelson W, Povia D, Kennedy TP, Piantodosi CA. Tyloxapol inhibits NF-kappa b and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum. Am J Respir Crit Care Med. 1996;154(3 Pt 1):783–88. doi:10.1164/ajrccm.154.3.8810619.
   PubMed Web of Science ®Google Scholar
• Daull P, Guenin S, Hamon de Almeida V, Garrigue JS. Anti-inflammatory activity of CKC-containing cationic emulsion eye drop vehicles. Mol Vis. 2018;24:459–70.
   PubMed Web of Science ®Google Scholar
• Lee HS, Hattori T, Park EY, Stevenson W, Chauhan SK, Dana R. Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease. Invest Ophthalmol Vis Sci. 2012;53(9):5632–40. doi:10.1167/iovs.12-9547.
   PubMed Web of Science ®Google Scholar
• Redfern RL, Barabino S, Baxter J, Lema C, McDermott AM. Dry eye modulates the expression of toll-like receptors on the ocular surface. Exp Eye Res. 2015;134:80–89. doi:10.1016/j.exer.2015.03.018.
   PubMed Web of Science ®Google Scholar
• Eslani M, Movahedan A, Afsharkhamseh N, Sroussi H, Djalilian AR. The role of toll-like receptor 4 in corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2014;55(9):6108–15. doi:10.1167/iovs.14-14736.
   PubMed Web of Science ®Google Scholar
• Shen L, Barabino S, Taylor AW, Dana MR. Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol. 2007;125(7):908–15. doi:10.1001/archopht.125.7.908.
   PubMedGoogle Scholar
• Veldhoen M, Stockinger B. Tgfbeta1, a “jack of all trades”: the link with pro-inflammatory il-17-producing t cells. Trends Immunol. 2006;27(8):358–61. doi:10.1016/j.it.2006.06.001.
   PubMed Web of Science ®Google Scholar
• Okamura T, Morita K, Iwasaki Y, Inoue M, Komai T, Fujio K, Yamamoto K. Role of tgf-beta3 in the regulation of immune responses. Clin Exp Rheumatol. 2015;33:S63–69.
   PubMed Web of Science ®Google Scholar
• Sugaya S, Sakimoto T, Shoji J, Sawa M. Regulation of soluble interleukin-6 (il-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol. 2011;55(3):277–82. doi:10.1007/s10384-011-0002-x.
   PubMed Web of Science ®Google Scholar
• Kucherenko AM, Pampukha VM, Drozhzhyna GI, Livshits LA. Il1beta, il6 and il8 gene polymorphisms involvement in recurrent corneal erosion in patients with hereditary stromal corneal dystrophies. Tsitol Genet. 2013;47:42–45.
   PubMedGoogle Scholar
• Choi W, Noh H, Yeo A, Jang H, Ahn HK, Song YJ, Lee HK. The effect of TNF-α blocker hl036337 and its best concentration to inhibit dry eye inflammation. Korean J Ophthalmol. 2016;30(4):302–08. doi:10.3341/kjo.2016.30.4.302.
   PubMedGoogle Scholar